Benitec reports Q3 net loss $4.3M, positive OPMD data, $40M PIPE closed

Benitec Biopharma Inc.

2024-Q3 EPS reported -$6.95

Net loss of $4.3M ($1.64 EPS) vs $4.4M ($2.67 EPS) in Q3 2023; revenue $0.
Cash $14.1M at Mar 31; subsequent $40M oversubscribed PIPE closed Apr 22 extends runway through 2025.
First OPMD subject showed clinically meaningful improvements in swallowing at 90 days post BB-301 dose; no SAEs.
Second subject dosed safely; third expected June 2024; 23 subjects enrolled in natural history study.
Additional interim safety/efficacy data expected H2 2024; Suvretta Capital led PIPE.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Benitec Biopharma Inc. reported third fiscal quarter ended March 31, 2024 results: revenue $0.

Period: third fiscal quarter ended March 31, 2024
Revenue: $0
Result: reported results

Exact text from the filing

Total Revenues for the quarter ended March 31, 2024, were $0 compared to $54,000 in licensing revenues collected for the quarter ended March 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-136730

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.